Drug Delivery Strategies and Nanozyme Technologies to Overcome Limitations for Targeting Oxidative Stress in Osteoarthritis
Pharmaceuticals · 23.07.2023 · 16 (7) · 1044
DOI: 10.3390/ph16071044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 23.07.2023. Verfasst von Jessica Lee Aldrich und 3 weiteren Autor:innen. Beteiligte Einrichtung: J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Oxidative stress is an important, but elusive, therapeutic target for osteoarthritis (OA). Antioxidant strategies that target oxidative stress through the elimination of reactive oxygen species (ROS) have been widely evaluated for OA but are limited by the physiological characteristics of the joint. Current hallmarks in antioxidant treatment strategies include poor bioavailability, poor stability, and poor retention in the joint. For example, oral intake of exogenous antioxidants has limited access to the joint space, and intra-articular injections require frequent dosing to provide therapeutic effects. Advancements in ROS-scavenging nanomaterials, also known as nanozymes, leverage bioactive material properties to improve delivery and retention. Material properties of nanozymes can be tuned to overcome physiological barriers in the knee. However, the clinical application of these nanozymes is still limited, and studies to understand their utility in treating OA are still in their infancy. The objective of this review is to evaluate current antioxidant treatment strategies and the development of nanozymes as a potential alternative to conventional small molecules and enzymes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.
ORCID-Profile: Robert Ovalle
Förderung
- NIAMS NIH HHS
- NIH HHS
- National Institute of Health
- National Institute on Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Aldrich, J. L., Panicker, A., Ovalle, R., & Sharma, B. (2023). Drug Delivery Strategies and Nanozyme Technologies to Overcome Limitations for Targeting Oxidative Stress in Osteoarthritis. Pharmaceuticals, 16(7), 1044. https://doi.org/10.3390/ph16071044
Vancouver
Aldrich JL, Panicker A, Ovalle R, Sharma B. Drug Delivery Strategies and Nanozyme Technologies to Overcome Limitations for Targeting Oxidative Stress in Osteoarthritis. Pharmaceuticals. 2023;16(7):1044. doi:10.3390/ph16071044
BibTeX
@article{Aldrich2023,
author = {Aldrich, Jessica Lee and Panicker, Arjun and Ovalle, Robert and Sharma, Blanka},
title = {Drug Delivery Strategies and Nanozyme Technologies to Overcome Limitations for Targeting Oxidative Stress in Osteoarthritis},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {7},
pages = {1044},
doi = {10.3390/ph16071044}
}
EUVIMED